Embed Size (px)
DESCRIPTION
Stempeutics Research is a one of the few companies in India engaged in development of Regenerative Medicine. Since its inception in 2006, it has built a strong pipeline of products, some of which are in Phase II trials. Promoted by Karnataka’s Manipal Group, which has interests in education and healthcare, the company has facilities in Bangalore and Manipal (India) as well as in Kuala Lumpur (Malaysia). Stempeutics strives towards building strong IP portfolio and is proactively engaged in extensive research in the area of stem cell technology and its application. To build a strong patent portfolio, we seek patent protection for our innovations at national and international levels. Stempeutics has been granted two patents in India and one patent in South Africa. Stempeutics has filed 9 patents in India, 2 patents in US, 9 patents in Malaysia and 14 patents across various countries around the globe
Citation preview
STEMPEUTICS RESEARCH PVT LTD
Company Report: India-Regenerative Medicine-Unlisted 15 MAY 2014
www.indiabusinessreports.com
COMPANY BACKGROUND
Beginning
Stempeutics Research is a one of the few companies in India engaged in development of Regenerative Medicine. Since its inception in 2006, it has built a strong pipeline of products, some of which are in Phase II trials.
Promoted by Karnataka’s Manipal Group, which has interests in education and healthcare, the company has facilities in Bangalore and Manipal (India) as well as in Kuala Lumpur (Malaysia).
Stempeutics strives towards building strong IP portfolio and is proactively engaged in extensive research in the area of stem cell technology and its application. To build a strong patent portfolio, we seek patent protection for our innovations at national and international levels.
Stempeutics has been granted two patents in India and one patent in South Africa. Stempeutics has filed 9 patents in India, 2 patents in US, 9 patents in Malaysia and 14 patents across various countries around the globe
XXXXXXXXXXXXx
XXXXXXXXXXXXXxx
Board of Directors Name Designation
Hebri Sudarshan Ballal Chairman
Manohar BN MD
Chandrasekaran Madhavan Director
Geena Vinod Malhotra Director
Jaydeep Ashok Gogtay Director
Ranjan Pai Director
Address
Akshay Tech Park, #72 & 73, 2nd Floor , EPIP Zone, Phase I-Area Whitefield, Bangalore, Karnataka - 560066
Financial Summary
Year ending June 30 FY11 FY12 FY13
Net Sales (Rs mn)
EBITDA (Rs mn)
EBITDA Margin (%)
PAT (Rs mn)
Net worth (Rs mn)
Debt (Rs mn)
Sales Growth (%)
PAT Growth (%)
ROE (%)
ROCE (%)
D/E (x)
Name of Auditors
SRIRAMULU NAIDU & CO
To get a free copy* of this report with full content, write to [email protected] *free for students and academicians
India-Regenerative Med-Unlisted Stempeutics Research 15 May’14
www.indiabusinessreports.com 2
Promoters Stemeutics is promoted by the Manipal Group, which has interests in healthcare and education. Cipla
Name No of Shares (%)
Ranjan Pai
MNI Ventures
Meditab Specialities Pvt Ltd Manipal Education and Medical
Group India Pvt Ltd
Total 3,06,24,644 100.0%
As of Sep’13
BUSINESS HIGHLIGHTS
XXXXXXXXX
XXXXXXXXX
XXXXXXXXX
XXXXXXXXX
MANUFACTURING FACILITIES
XXXXXXXXX
XXXXXXXXX
XXXXXXXXX
PEERS
XXXXXXXXX
XXXXXXXXX
India-Regenerative Med-Unlisted Stempeutics Research 15 May’14
www.indiabusinessreports.com 3
XXXXXXXXX
FINANCIAL PERFORMANCE
XXXXXXXXX
XXXXXXXXX
FUNDING AND FUTURE PLANS
XXXXXXXXX
XXXXXXXXX
XXXXXXXXX
.
India-Regenerative Med-Unlisted Stempeutics Research 15 May’14
www.indiabusinessreports.com 4
FINANCIAL DETAILS
P&L (Rs mn) FY09 FY10 FY11 FY12 FY13
Net Sales
EBITDA
Margin (%)
Interest
Other Income
PBDT
Depreciation
Extraordinary Item
PBT
PAT
PAT Margin (%)
Balance Sheet
(Rs mn) FY11 FY12 FY13
Liabilities
Equity Capital
Reserves
Shareholder Funds
Debt
Deferred tax liability
Other Long Term Lialilites
Total Liabilities
Assets
Fixed Assets (net)
Intangible Assets
Investments
Total Non Current Assets
Inventories
Debtors
Cash
Loans & Advances
Other CA
CL & Provisions
Net Current Assets
Deferred Tax Asset
India-Regenerative Med-Unlisted Stempeutics Research 15 May’14
www.indiabusinessreports.com 5
Total Assets
Ratios
FY11 FY12 FY13
Growth (%) Sales
PBDIT
PBT
PAT
Margins (%) PBDIT
PAT
Balance Sheet Ratios ROE (%)
ROCE (%)
D/E (x)
About India Business Reports India Business Reports (IBR) is an initiative of experienced professionals with comprehensive experience across wide domains – Research, Investment Banking, Private Equity Funding, Consulting, Branding and Marketing. The single minded objective at IBR is to generate insightful reports based on hard facts. Our expertise is relevant not only for the financial fraternity, but also global MNCs looking to do business with India, and Indian companies looking to fine tune their growth strategies. So be it India entry strategies, growth strategies, M&A opportunities or private equity investments, our reports can become a powerful tool in many ways. IBR typically does custom research, on request from clients. The reports shown on our website are sample reports for marketing purposes. These are available free for students and academia. We may impose a charge for corporate users. Disclaimer This note is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. The content in this note is solely for informational purpose and is not a solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this note constitutes investment, legal, accounting and tax advice. India Business Reports or its owner-partners accept no liabilities for any loss or damage of any kind arising out of the use of this note. Contact [email protected]; +91 99 87 474021
